The development of more effective vaccines against Mycobacterium tuberculosis has
become a world priority. Previously, we have shown that a recombinant BCG expressing the …

Pulmonary tuberculosis (TB) caused by Mycobacterium tuberculosis (Mtb) is a leading
cause of global morbidity and mortality. The only licensed TB vaccine, Mycobacterium bovis …

The development of effective vaccines against bacterial lung infections requires the
induction of protective, pathogen-specific immune responses without deleterious …

The ESAT-6 antigen from Mycobacterium tuberculosis is a dominant target for cell-mediated
immunity in the early phase of tuberculosis (TB) in TB patients as well as in various animal …

The only licensed vaccine Mycobacterium bovis Bacillus Calmette–Guérin (BCG) cannot
prevent the prevalence of tuberculosis (TB), which remains a major public health problem …

Background: Currently, there is no tuberculosis (TB) vaccine recommended for use in latent
TB infections and healthy adults. M72/AS01E is a new peptide vaccine currently under …

With almost a dozen vaccine candidates in clinical trials, tuberculosis (TB) research and
development is finally reaping the first fruits of its labors. Vaccine candidates in clinical trials …

Despite the dramatic reduction in the number of leprosy cases worldwide in the 1990s,
transmission of the causative agent, Mycobacterium leprae, is still occurring, and new cases …

Ag85b and HspX of Mycobacterium tuberculosis (Mtb)(H37Rv) were expressed and purified
in this study. These two proteins were combined with another fusion protein CFP-10: ESAT-6 …

Unlike most pathogens, many of the immunodominant epitopes from Mycobacterium
tuberculosis are under purifying selection. This startling finding suggests that M. tuberculosis …